con

Biocon Limited 20th KM Electronics City Ban galore 560 100, Date of submission: 02"d May, 2018 T 9 1 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA 1978PLC0034 17

www..com To To The Secretary Th e Secretary Li sting Department Listing Department BSE Limited National Stock Exchange of India Limited Department of Corporate Services Exchange Plaza, Bandra Ku rla Complex Phiroze Jeejeebhoy Towers, Mumbai - 400 050 Dalal Street, Mumbai - 400 001 Scrip Code- BIOCON Scrip Code - 532523

Dear Sir/Madam,

Sub: Biocon Regulatory Audit Update

Ref: Regu lations 30 of SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015.

Pursuant to Regulation 30 of the SEBI LODR Regu latio ns, 2015, please find below the company statement on the subject matter:

"The US-FDA has completed a pre-approval inspection of our sterile drug product manufacturing facility in this week and issued a Form 483 with 7 observations. The observations are largely procedural and aimed at continuous improvement. We will respond to the FDA with a corrective and preventive action plan in a timely manner.

We have also this week received the preliminary report from the European Regulator post inspection of our sterile drug product facility in Bangalore in March 2018. The report lists 6 major observations with no observation classified as critical. We will submit a corrective and preventive action plan to the European inspection agency within the stipulated time period." - Biocon Spokesperson

We request you to kindly take this is your record as per t he requirement of Li st ing Regulations and oblige.

Thanking You, Yours faithfully For Biocon Limited L o Akhilesh Nand Ch ief Compliance Officer